相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Multicenter Phase II Study of Neoadjuvant Lapatinib and Trastuzumab With Hormonal Therapy and Without Chemotherapy in Patients With Human Epidermal Growth Factor Receptor 2-Overexpressing Breast Cancer: TBCRC 006
Mothaffar F. Rimawi et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
First-Line Treatment Patterns and Clinical Outcomes in Patients With HER2-Positive and Hormone Receptor-Positive Metastatic Breast Cancer From registHER
Debu Tripathy et al.
ONCOLOGIST (2013)
Survival and clinicopathological characteristics of breast cancer patient according to different tumour subtypes as determined by hormone receptor and Her2 immunohistochemistry. A single institution survey spanning 1998 to 2010
A. Garcia Fernandez et al.
BREAST (2012)
Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - Results of the eLEcTRA trial
J. Huober et al.
BREAST (2012)
1st International consensus guidelines for advanced breast cancer (ABC 1)
F. Cardoso et al.
BREAST (2012)
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patients
Filippo Montemurro et al.
CANCER (2012)
S5-2: PAM50 HER2−Enriched Subtype Enriches for Tumor Response to Neoadjuvant Anthracyclines/Taxane and Trastuzumab/Taxane Containing Regimens in HER2−Positive Breast Cancer.
MCU Cheang et al.
CANCER RESEARCH (2012)
Cytoplasmic Estrogen Receptor in Breast Cancer
Allison W. Welsh et al.
CLINICAL CANCER RESEARCH (2012)
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial
Jose Baselga et al.
LANCET (2012)
Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial
Michael Untch et al.
LANCET ONCOLOGY (2012)
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial
Luca Gianni et al.
LANCET ONCOLOGY (2012)
Comprehensive molecular portraits of human breast tumours
Daniel C. Koboldt et al.
NATURE (2012)
Pertuzumab plus Trastuzumab plus Docetaxel for Metastatic Breast Cancer
Jose Baselga et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
ER and HER2 expression are positively correlated in HER2 non-overexpressing breast cancer
Isabel Pinhel et al.
BREAST CANCER RESEARCH (2012)
Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011
A. Goldhirsch et al.
ANNALS OF ONCOLOGY (2011)
Randomized Phase II Study Comparing Efficacy and Safety of Combination-Therapy Trastuzumab and Docetaxel vs. Sequential Therapy of Trastuzumab Followed by Docetaxel Alone at Progression As First-Line Chemotherapy in Patients with HER2+ Metastatic Breast Cancer: HERTAX Trial
Paul Hamberg et al.
CLINICAL BREAST CANCER (2011)
Reduced Dose and Intermittent Treatment with Lapatinib and Trastuzumab for Potent Blockade of the HER Pathway in HER2/neu-Overexpressing Breast Tumor Xenografts
Mothaffar F. Rimawi et al.
CLINICAL CANCER RESEARCH (2011)
Trastuzumab Emtansine (T-DM1) Vs Trastuzumab Plus Docetaxel (H+T) in Previously-untreated HER2-positive Metastatic Breast Cancer (MBC): Primary Results of a Randomized, Multicenter, Open-label Phase II Study (TDM4450 g/BO21976)
S. Hurvitz et al.
EUROPEAN JOURNAL OF CANCER (2011)
Multicenter Phase III Randomized Trial Comparing Docetaxel and Trastuzumab With Docetaxel, Carboplatin, and Trastuzumab As First-Line Chemotherapy for Patients With HER2-Gene-Amplified Metastatic Breast Cancer (BCIRG 007 Study): Two Highly Active Therapeutic Regimens
Vicente Valero et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Phase III Randomized Study Comparing Docetaxel Plus Trastuzumab With Vinorelbine Plus Trastuzumab As First-Line Therapy of Metastatic or Locally Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: The HERNATA Study
Michael Andersson et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials
C. Davies et al.
LANCET (2011)
HER2 and hormone receptor-positive breast cancer-blocking the right target
Javier Cortes et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2011)
Adjuvant Trastuzumab in HER2-Positive Breast Cancer
Dennis Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Different mechanisms for resistance to trastuzumab versus lapatinib in HER2-positive breast cancers - role of estrogen receptor and HER2 reactivation
Yen-Chao Wang et al.
BREAST CANCER RESEARCH (2011)
Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group
Kenichi Inoue et al.
BREAST CANCER RESEARCH AND TREATMENT (2010)
Identification of a low-risk subgroup of HER-2-positive breast cancer by the 70-gene prognosis signature
M. Knauer et al.
BRITISH JOURNAL OF CANCER (2010)
Randomized Phase II Trial of First-Line Trastuzumab Plus Docetaxel and Capecitabine Compared With Trastuzumab Plus Docetaxel in HER2-Positive Metastatic Breast Cancer
Andrew M. Wardley et al.
JOURNAL OF CLINICAL ONCOLOGY (2010)
Lapatinib plus Letrozole as First-Line Therapy for HER-2(+) Hormone Receptor-Positive Metastatic Breast Cancer
Lee S. Schwarzberg et al.
ONCOLOGIST (2010)
Subtyping of Breast Cancer by Immunohistochemistry to Investigate a Relationship between Subtype and Short and Long Term Survival: A Collaborative Analysis of Data for 10,159 Cases from 12 Studies
Fiona M. Blows et al.
PLOS MEDICINE (2010)
Proteomic and transcriptomic profiling reveals a link between the PI3K pathway and lower estrogen-receptor (ER) levels and activity in ER plus breast cancer
Chad J. Creighton et al.
BREAST CANCER RESEARCH (2010)
Increasing steroid hormone receptors expression defines breast cancer subtypes non responsive to preoperative chemotherapy
Marco Colleoni et al.
BREAST CANCER RESEARCH AND TREATMENT (2009)
Breast Cancer Subtypes as Defined by the Estrogen Receptor (ER), Progesterone Receptor (PR), and the Human Epidermal Growth Factor Receptor 2 (HER2) among Women with Invasive Breast Cancer in California, 1999-2004
Carol A. Parise et al.
BREAST JOURNAL (2009)
Novel Mechanism of Lapatinib Resistance in HER2-Positive Breast Tumor Cells: Activation of AXL
Li Liu et al.
CANCER RESEARCH (2009)
Lapatinib Combined With Letrozole Versus Letrozole and Placebo As First-Line Therapy for Postmenopausal Hormone Receptor-Positive Metastatic Breast Cancer
Stephen Johnston et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2-Positive, Hormone Receptor-Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study
Bella Kaufman et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Estimating the magnitude of trastuzumab effects within patient subgroups in the HERA trial
M. Untch et al.
ANNALS OF ONCOLOGY (2008)
Relationship between quantitative estrogen and progesterone receptor expression and human epidermal growth factor receptor 2 (HER-2) status with recurrence in the arimidex, tamoxifen, alone or in combination trial
Mitch Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Efficacy and safety of lapatinib as first-line therapy for ErbB2-amplified locally advanced or metastatic breast cancer
Henry L. Gomez et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Phase III, Double-Blind, Randomized Study Comparing Lapatinib Plus Paclitaxel With Placebo Plus Paclitaxel As First-Line Treatment for Metastatic Breast Cancer
Angelo Di Leo et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
HER2 status and efficacy of adjuvant anthracyclines in early breast cancer:: A pooled analysis of randomized trials
Alessandra Gennari et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2008)
Adjuvant letrozole versus tamoxifen according to centrally-assessed ERBB2 status for postmenopausal women with endocrine-responsive early breast cancer: supplementary results from the BIG 1-98 randomised trial
Birgitte B. Rasmussen et al.
LANCET ONCOLOGY (2008)
Estrogen receptors outside the nucleus in breast cancer
Ellis R. Levin et al.
BREAST CANCER RESEARCH AND TREATMENT (2008)
Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy
Grazia Arpino et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2007)
Estrogen-independent proliferation is present in estrogen-receptor HER2-positive primary breast cancer after neoadjuvant letrozole
Matthew J. Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
EGF-ERBB signalling: towards the systems level
Ami Citri et al.
NATURE REVIEWS MOLECULAR CELL BIOLOGY (2006)
Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer
Nicholas Robert et al.
JOURNAL OF CLINICAL ONCOLOGY (2006)
A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer
Wenle Xia et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2006)
Benefit from adjuvant tamoxifen therapy in primary breast cancer patients according oestrogen receptor, progesterone receptor, EGF receptor and HER2 status
M Dowsett et al.
ANNALS OF ONCOLOGY (2006)
Reverting estrogen-receptor-negative phenotype in HER-2-overexpressing advanced breast cancer patients exposed to trastuzumab plus chemotherapy
E Munzone et al.
BREAST CANCER RESEARCH (2006)
Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer
MJ Piccart-Gebhart et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer
EH Romond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2005)
Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment:: The M77001 study group
M Marty et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer
M De Laurentiis et al.
CLINICAL CANCER RESEARCH (2005)
Biomarker changes during neoadjuvant anastrozole, tamoxifen, or the combination: Influence of hormonal status and HER-2 in breast cancer - A study from the IMPACT trialists
M Dowsett et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Phase II study of efficacy, safety, and pharmacokinetics of trastuzumab monotherapy administered on a 3-weekly schedule
J Baselga et al.
JOURNAL OF CLINICAL ONCOLOGY (2005)
Correlation of HER-2 status with estrogen and progesterone receptors and histologic features in 3,655 invasive breast carcinomas
P Lal et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2005)
Growth factor signalling networks in breast cancer and resistance to endocrine agents: new therapeutic strategies
RI Nicholson et al.
JOURNAL OF STEROID BIOCHEMISTRY AND MOLECULAR BIOLOGY (2005)
Forkhead box transcription factor FOXO3a regulates estrogen receptor alpha expression and is repressed by the Her-2/neu/phosphatidylinositol 3-kinase/Akt signaling pathway
SQ Guo et al.
MOLECULAR AND CELLULAR BIOLOGY (2004)
Selective phosphorylations of the SRC-3/AIB1 coactivator integrate genomic reponses to multiple cellular signaling pathways
RC Wu et al.
MOLECULAR CELL (2004)
HER-2 amplification, HER-1 expression, and tamoxifen response in estrogen receptor-positive metastatic breast cancer: A southwest oncology group study
G Arpino et al.
CLINICAL CANCER RESEARCH (2004)
A multigene assay to predict recurrence of tamoxifen-treated, node-negative breast cancer
S Paik et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer
J Shou et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Rational combinations of trastuzumab with chemotherapeutic drugs used in the treatment of breast cancer
MD Pegram et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2004)
Identification of a structural determinant necessary for the localization and function of estrogen receptor α at the plasma membrane
M Razandi et al.
MOLECULAR AND CELLULAR BIOLOGY (2003)
HER-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer
RR Love et al.
JOURNAL OF CLINICAL ONCOLOGY (2003)
Quantitative association between, HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer
G Konecny et al.
JOURNAL OF THE NATIONAL CANCER INSTITUTE (2003)
Efficacy and safety of trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast cancer
CL Vogel et al.
JOURNAL OF CLINICAL ONCOLOGY (2002)
Resistance to tamoxifen-induced apoptosis is associated with direct interaction between Her2/neu and cell membrane estrogen receptor in breast cancer
YL Chung et al.
INTERNATIONAL JOURNAL OF CANCER (2002)
Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer:: Evidence from a phase III randomized trial
MJ Ellis et al.
JOURNAL OF CLINICAL ONCOLOGY (2001)
Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2.
DJ Slamon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2001)
HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
DA Berry et al.
JOURNAL OF CLINICAL ONCOLOGY (2000)
AIB1 is a conduit for kinase-mediated growth factor signaling to the estrogen receptor
JF de Mora et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)
Transcriptional activation of transforming growth factor α by estradiol:: requirement for both a GC-rich site and an estrogen response element half-site
C Vyhlidal et al.
JOURNAL OF MOLECULAR ENDOCRINOLOGY (2000)
The SMRT corepressor is regulated by a MEK-1 kinase pathway: Inhibition of corepressor function is associated with SMRT phosphorylation and nuclear export
SH Hong et al.
MOLECULAR AND CELLULAR BIOLOGY (2000)